Treatment
Table 1. Reasonable Doses and Schedules by Recommendation
Note: only recommendations with recommended therapy are listed
IDH-mutant Astrocytic and Oligodendroglial Tumors
Recommendation Therapy Dose and Schedule Source
Recommendation 1.1
(IDH-mutant,
1p/19q codeleted
oligodendroglioma
[CNS WHO grade 2])
and
Recommendation1.4
(IDH-mutant, 1p/19q
non-codeleted diffuse
astrocytoma [CNS
WHO grade 2])
Radiation 54 Gy in 30 fractions
over 6 weeks
As used in the
RTOG 9802
trial
Adjuvant PCV Procarbazine 60 mg/m
2
orally per day days 8
through 21, lomustine
110 mg/m
2
orally on
day 1, and vincristine
1.4 mg/m
2
IV on days 8
and 29 in 8 week cycle
for a total of six cycles
As used in the
RTOG 9802
trial and as used
in the EORTC
26951 trial
Adjuvant
temozolomide
150–200 mg/m
2
adjuvant temozolomide
given on days 1–5 every
4 weeks for a maximum
of 12 months
As used in the
CATNON trial
Recommendation 1.3
(IDH-mutant, 1p/19q
co-deleted, anaplastic
oligodendroglioma
[CNS WHO grade 3])
Radiation 59.4 Gy in 33 fractions at
5 fractions per week
As used in the
EORTC 26951
trial
Adjuvant PCV As in 1.1 and 1.4
Adjuvant
temozolomide
As in 1.1 and 1.4
Recommendation 1.6
(IDH-mutant, 1p/19q
non-codeleted anaplastic
astrocytoma [CNS
WHO grade 3])
Radiation 59.4 Gy given in 33
fractions of 1.8 Gy
As used in the
CATNON trial
Adjuvant
temozolomide
As in 1.1 and 1.4 As used in the
CATNON trial
Glioblastoma and Other IDH-Wildtype Diffuse Glioma
Recommendation
2.2 and 2.3
(newly diagnosed
glioblastoma)
Radiation 60 Gy in 2 Gy fractions 5
fractions a week
As used in the
EORTC 26981-
22981 trial
Concurrent
temozolomide
75 mg/m
2
daily
temozolomide during
radiation therapy
As used in the
EORTC 26981-
22981 trial
Adjuvant
temozolomide
150–200 mg/m
2
for 5
out of 28 consecutive
days for a maximum of
6 months
As used in the
EORTC 26981-
22981 trial
